


Breast cancer is a challenge best faced together

Axillary management after neoadjuvant treatment

Neoadjuvant systemic therapy (NAST) facts




Why is NAST beneficial for breast cancer patients?

Aim: de-escalation of cancer treatment

- ✓ Shrink or eradicate the tumour in the breast and lymph nodes
- ✓ Monitor systemic therapy response and its modification, if required
- ✓ Enable less radical cancer surgery in breast and axilla (BCS and TAD)
- ✓ Fewer co-morbidities and better cosmetic outcome lead to improved quality of life for patients

How does TAD improve axillary staging post-NAST?

Improving the accuracy, reducing the false negative rate (FNR)





Tracer guided SLNB is combined with the removal of a previously positive and marked lymph node (target lymph node)

Sysmex solution for TAD

MAGSEED® PLACEMENT

Benefits of Magseed® for marking target lymph nodes

- ✓ Simple and easy to place
- Designed with the patient in mind no radioactivity, reduced stress, less pain
- ✓ Smallest non-radioactive seed ideal for lymph node placement
- ✓ Spiral shape optimises tissue in-growth and visibility under imaging



IMPLANTATION TIME DURING NAST

Perfect orientation from placement to detection

- ✓ Can be implanted for as long as needed always realiably detectable by Sentimag®
- ✓ Surgical steel marker, very low nickel content
- ✓ Firmly implanted, no migration from soft tissue
- ✓ The patient won't feel it
- ✓ Visible under US and X-ray
- ✓ No risk of deactivation



SURGERY

Sentimag®-Magseed®/Magtrace® – the world's only system for wire-free, non-radioactive TAD³

Both the Magseed® and Magtrace® are precisely located intraoperatively by the Sentimag® probe.

Magseed® magnetic marker



Placement success in lymph nodes

Retrieval rate

Magtrace® lymphatic tracer for SLNB

Nodal detection

2.0 – Average number of excised sentinel nodes per patient

50,000 SLNBs across 35+ countries

DIAGNOSIS

- Accurate molecular sentinel lymph node assessment with OSNA
- ✓ Standardised and accurate results thanks to whole node analysis
- ✓ Highly sensitive amplification technology and quantification of metastatic burden
- ✓ No risk to overlook low volume residual disease
- ✓ 16 minutes to get a fully informed result
- ✓ Reliable intraoperative decision-making
- ✓ No risk of second surgeries due to false negative intraoperative results

